Insight Molecular Diagnostics presents GraftAssure rollout plans with seven US centers in validation
IMDX•
IMDX•Seven US transplant centers are validating GraftAssure, with launches expected in 2027. The centers represent about 7% of annual US kidney transplant volume, supporting a steady-state annual revenue target above $15 million.
Seven US transplant centers are validating GraftAssure, and launches are expected in 2027. The centers represent about 7% of annual US kidney transplant volume, supporting an annual revenue target above $15 million at steady state.
GraftAssureDx remains under FDA review for commercial use following its March 2026 submission. Medicare reimbursement for GraftAssureCore is $2,753 per result.
Bio-Rad is a top-five shareholder following four equity investments, and GraftAssure assays run on its instruments.